Stock Events

Stock Events

Relmada Therapeutics 

€6.3
36
+€0+0% Monday 06:03

Statistics

Day High
6.3
Day Low
6.3
52W High
6.3
52W Low
0.26
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2025
Next
-0.23
-0.2
-0.16
-0.13
Expected EPS
-0.17048934
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4E2.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.69B
Alkermes develops treatments for major depressive disorder and other central nervous system disorders, overlapping with Relmada's focus.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical division Janssen, offers products that compete in the mental health space.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly has a strong portfolio in psychiatric and neurological conditions, directly competing with Relmada's offerings.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad range of products for neurological and psychiatric conditions, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical Industries has a focus on CNS and pain, areas that Relmada is also targeting.
Novartis
NVS
Mkt Cap279.67B
Novartis offers medications for a wide range of neurological conditions, competing in the same market as Relmada.
Merck
MRK
Mkt Cap277.02B
Merck & Co. has initiatives in brain health, including treatments for conditions that Relmada targets.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has a growing portfolio in neuroscience, including treatments for psychiatric disorders.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb has a diverse neuroscience portfolio, making it a competitor in the mental health treatment market.

About

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Show more...
CEO
Dr. Sergio Traversa M.B.A., Pharm.D.
Employees
17
Country
United States
ISIN
US75955J4022

Listings

STU
DE
4E2.STU
MU
DE
4E2.MU
XNAS
US
RLMD
F
DE
4E2.F

0 Comments

Share your thoughts

FAQ

What is Relmada Therapeutics stock price today?▼
The current price of 4E2.MU is €6.3 EUR — it has increased by +0% in the past 24 hours. Watch Relmada Therapeutics stock price performance more closely on the chart.
What is Relmada Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Relmada Therapeutics stocks are traded under the ticker 4E2.MU.
Is Relmada Therapeutics stock price growing?▼
4E2.MU stock has risen by +2.44% compared to the previous week, the month change is a +7.69% rise, over the last year Relmada Therapeutics has showed a +1,820.73% increase.
When is the next Relmada Therapeutics earnings date?▼
Relmada Therapeutics is going to release the next earnings report on May 13, 2026.
What were Relmada Therapeutics earnings last quarter?▼
4E2.MU earnings for the last quarter are -0.23 EUR per share, whereas the estimation was -0.13 EUR resulting in a -81.67% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Relmada Therapeutics have?▼
As of May 07, 2026, the company has 17 employees.
In which sector is Relmada Therapeutics located?▼
Relmada Therapeutics operates in the Health & Wellness sector.
When did Relmada Therapeutics complete a stock split?▼
Relmada Therapeutics has not had any recent stock splits.
Where is Relmada Therapeutics headquartered?▼
Relmada Therapeutics is headquartered in Coral Gables, United States.